Special Committee on Aging Frontruns Valeant Pharmaceuticals Q1 Earnings ReleaseGuest Post
Special Committee on Aging Frontruns Valeant Pharmaceuticals Q1 Earnings Release by BoredWithTheNoise
Entangled within the epic data dump the Senate Committee on Aging gave the world there is some troubling guidance provided by Valeant's CFO, Rob Rosiello. In response to the interrogatories posed by the committee regarding the pricing of a handful of Valeant Pharmaceuticals drugs, Mr. Rosiello (response starts on pg 17) was required to disclose the ratio of revenues that each of those drugs represented in relation to company wide numbers. To set the baseline for . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email firstname.lastname@example.org or click chat